Clinical data have reinforced this concept, with patients with IBD on anti-TNF therapy exhibiting reduced hepatic steatosis markers compared to those not on biologics, suggesting that TNF inhibition might mitigate hepatic fat accumulation [23]. The gene discussed is TNF; the disease is inflammatory bowel disease.